Gary Middleton
- Oncology top 0.2%
- Colorectal Cancer Treatments and Studies 46
- Cancer Immunotherapy and Biomarkers 32
- Pancreatic and Hepatic Oncology Research 16
- Lung Cancer Research Studies 13
- Gastroenterology top 0.5%
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations 41
- Gastric Cancer Management and Outcomes 23
- Immunology top 2%
- Immune Cell Function and Interaction 13
- Cancer Research top 2%
- Cancer Genomics and Diagnostics 30
- Co-authors
- Leisha A. EmensDavid CunninghamFareeda Y. CoxonTimothy IvesonA. NormanM. NicolsonNaureen StarlingSheela Rao
- Journals
- Journal of Clinical Oncology (40 papers)Annals of Oncology (19 papers)British Journal of Cancer (10 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
Gary Middleton
170 papers receiving 8.7k citations
Hit Papers
Peers
Comparison fields: 5 of 125
- Oncology 5.4k
- Gastroenterology 976
- Pulmonary and Respiratory Medicine 4.2k
- Immunology 1.4k
- Cancer Research 837
Countries citing papers authored by Gary Middleton
This map shows the geographic impact of Gary Middleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Middleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Middleton more than expected).
Fields of papers citing papers by Gary Middleton
This network shows the impact of papers produced by Gary Middleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Middleton. The network helps show where Gary Middleton may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Gary Middleton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 25 | |
| 5 | 2024 | 5 | |
| 6 | 2023 | 1 | |
| 7 | 2023 | 13 | |
| 8 | 2023 | 41 | |
| 9 | 2023 | 6 | |
| 10 | 2021 | 25 | |
| 11 | COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study | 2020 | 4 |
| 12 | 2019 | 1 | |
| 13 | 2018 | 43 | |
| 14 | 2017 | 112 | |
| 15 | FOCUS4: MAMS Trial Design in Action. Early Closure of FOCUS4-D (Pan-HER 1, 2 and 3 Inhibitor Versus Placebo) in Advanced Colorectal Cancer (aCRC) Patients, with Tumours Wildtype (WT) for KRAS, NRAS, BRAF and PIK3CA | 2017 | 1 |
| 16 | 2017 | 15 | |
| 17 | 2013 | 19 | |
| 18 | 1992 | 12 | |
| 19 | 1984 | 63 | |
| 20 | Rapid detection of cow's milk in goat's milk. | 1980 | 2 |
About Gary Middleton
Gary Middleton is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 176 papers that have together received 8.9k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (46 papers), Lung Cancer Treatments and Mutations (41 papers), Cancer Immunotherapy and Biomarkers (32 papers), Cancer Genomics and Diagnostics (30 papers), Gastric Cancer Management and Outcomes (23 papers), Pancreatic and Hepatic Oncology Research (16 papers), Immune Cell Function and Interaction (13 papers) and Lung Cancer Research Studies (13 papers). The work is most often cited by research in Oncology (5.4k citations), Gastroenterology (976 citations) and Pulmonary and Respiratory Medicine (4.2k citations). Gary Middleton has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Leisha A. Emens, David Cunningham, Fareeda Y. Coxon, Timothy Iveson, A. Norman, M. Nicolson, Naureen Starling, Sheela Rao, Francis Daniel and J. Oates. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer, Nuclear Medicine Communications and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.